Alberto Puccini: Our Correspondence to the new ASCO Guidelines on the “Selection of germline genetic testing panels in patients with cancer”
Alberto Puccini, Medical Oncologist at Humanitas Cancer Center at Milan, Italy, posted on LinkedIn about recent paper by him as co-author, titled “Routinely Updating Patients With Cancer About Variant of Uncertain Significance Reclassifications: A Premature Responsibility for Community Oncologists” published on Journal of Clinical Oncology.
Authors: Linda Battistuzzi, Alberto Puccini, Stefania Sciallero, Maurizio Genuardi.
“Thrilled to see our Correspondence to the new ASCO Guidelines on the ‘Selection of germline genetic testing panels in patients with cancer’ published on Journal of Clinical Oncology.
We argue that asking community oncologists who order multigene panel testing to commit to recontact patients about VUS reclassification as a routine activity, in the absence of specific guidance, may overburden them with knowledge and organizational demands. Finally, we emphasize that there is a need to promote clarity and develop consensus around this important issue among different stakeholder groups.
Special thanks to my extraordinary colleagues and Experts in the field Linda Battistuzzi, Stefania Sciallero and Prof Maurizio Genuardi!”
Source: Alberto Puccini/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023